Your browser doesn't support javascript.
Salivary detection of COVID-19: clinical performance of oral sponge sampling for SARS-CoV-2 testing.
Boutros, Jacques; Benzaquen, Jonathan; Marquette, Charles Hugo; Ilié, Marius; Labaky, Mickelina; Benchetrit, Didier; Lavrut, Thibaut; Leroy, Sylvie; Chemla, Richard; Carles, Michel; Tanga, Virginie; Maniel, Charlotte; Bordone, Olivier; Allégra, Maryline; Lespinet, Virginie; Fayada, Julien; Griffonnet, Jennifer; Hofman, Véronique; Hofman, Paul.
  • Boutros J; Dept of Pulmonary Medicine and Thoracic Oncology, Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, FHU OncoAge, Nice, France.
  • Benzaquen J; Dept of Pulmonary Medicine and Thoracic Oncology, Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, FHU OncoAge, Nice, France.
  • Marquette CH; Université Côte d'Azur, CNRS, INSERM, Institute of Research on Cancer and Aging, Nice, France.
  • Ilié M; Dept of Pulmonary Medicine and Thoracic Oncology, Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, FHU OncoAge, Nice, France.
  • Labaky M; Université Côte d'Azur, CNRS, INSERM, Institute of Research on Cancer and Aging, Nice, France.
  • Benchetrit D; Université Côte d'Azur, CNRS, INSERM, Institute of Research on Cancer and Aging, Nice, France.
  • Lavrut T; Laboratory of Clinical and Experimental Pathology (LPCE), Université Côte d'Azur, FHU OncoAge, Centre Hospitalier Universitaire de Nice, Biobank (BB-0033-00025), Nice, France.
  • Leroy S; SYNLAB Barla, Nice, France.
  • Chemla R; SYNLAB Barla, Nice, France.
  • Carles M; Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Laboratoire de Virologie, CHU de Nice, Nice, France.
  • Tanga V; Dept of Pulmonary Medicine and Thoracic Oncology, Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, FHU OncoAge, Nice, France.
  • Maniel C; CNRS UMR 7275 - Institut de Pharmacologie Moléculaire et Cellulaire, Université Côte d'Azur, Nice, France.
  • Bordone O; Ville de Nice, Nice, France.
  • Allégra M; Dept of Infectious Diseases, Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, Nice, France.
  • Lespinet V; Laboratory of Clinical and Experimental Pathology (LPCE), Université Côte d'Azur, FHU OncoAge, Centre Hospitalier Universitaire de Nice, Biobank (BB-0033-00025), Nice, France.
  • Fayada J; Dept of Pulmonary Medicine and Thoracic Oncology, Université Côte d'Azur, Centre Hospitalier Universitaire de Nice, FHU OncoAge, Nice, France.
  • Griffonnet J; Laboratory of Clinical and Experimental Pathology (LPCE), Université Côte d'Azur, FHU OncoAge, Centre Hospitalier Universitaire de Nice, Biobank (BB-0033-00025), Nice, France.
  • Hofman V; Laboratory of Clinical and Experimental Pathology (LPCE), Université Côte d'Azur, FHU OncoAge, Centre Hospitalier Universitaire de Nice, Biobank (BB-0033-00025), Nice, France.
  • Hofman P; Laboratory of Clinical and Experimental Pathology (LPCE), Université Côte d'Azur, FHU OncoAge, Centre Hospitalier Universitaire de Nice, Biobank (BB-0033-00025), Nice, France.
ERJ Open Res ; 7(4)2021 Oct.
Article in English | MEDLINE | ID: covidwho-1562071
ABSTRACT

BACKGROUND:

The current diagnostic standard for coronavirus disease 2019 (COVID-19) is reverse transcriptase-polymerase chain reaction (RT-PCR) testing with nasopharyngeal (NP) swabs. The invasiveness and need for trained personnel make the NP technique unsuited for repeated community-based mass screening. We developed a technique to collect saliva in a simple and easy way with the sponges that are usually used for tamponade of epistaxis. This study was carried out to validate the clinical performance of oral sponge (OS) sampling for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing.

METHODS:

Over a period of 22 weeks, we collected prospectively 409 paired NP and OS samples from consecutive subjects presenting to a public community-based free screening centre. Subjects were referred by their attending physician because of recent COVID-19 symptoms (n = 147) or by the contact tracing staff of the French public health insurance because they were considered as close contacts of a laboratory-confirmed COVID-19 case (n = 262).

RESULTS:

In symptomatic subjects, RT-PCR SARS-CoV-2 testing with OS showed a 96.5% (95% CI 89.6-94.8) concordance with NP testing, and a 93.2% (95% CI 89.1-97.3) sensitivity when using the IdyllaTM platform and a sensitivity of 76.3% (95% CI 69.4-83.2) on the Synlab Barla laboratory platform. In close contacts the NP-OS concordance (93.8%, 95% CI 90.9-96.7) and OS sensitivity (71.9%, 95% CI 66.5-77.3) were slightly lower.

CONCLUSION:

These results strongly suggest that OS testing is a straightforward, low-cost and high-throughput sampling method that can be used for frequent RT-PCR testing of COVID-19 patients and mass screening of populations.

Full text: Available Collection: International databases Database: MEDLINE Type of study: Diagnostic study / Prognostic study Language: English Year: 2021 Document Type: Article Affiliation country: 23120541.00396-2021

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Diagnostic study / Prognostic study Language: English Year: 2021 Document Type: Article Affiliation country: 23120541.00396-2021